ENTERA BIO LTD. Contract Liability (Deferred Revenue)
ENTERA BIO LTD. (ENTX) had Contract Liability (Deferred Revenue) of $0 as of 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Balance Sheet › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2023-03-31
- 2022-12-31: Contract with Customer, Liability, Current $0.00.
- 2022-09-30: Contract with Customer, Liability, Current $0.00.
- 2022-06-30: Contract with Customer, Liability, Current $0.00.
- 2022-03-31: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-31 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-12 |
| 2021-12-31 | $15.00K 10-K · filed 2023-03-31 |
| 2020-12-31 | $158.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |